More influencers are promoting Korean sunscreens on social media, claiming that those sunscreens are better than the ones produced in the United States. The claim stems from the fact that Korea has access to more UV filters than the U.S. Whereas the U.S. has 16 UV filters approved by the Food and Drug Administration (FDA), Korea’s Ministry of Food and Drug Safety (MFDS) have approved approximately 30 and are still approving new generation filters.

 

The U.S. has not added a new UV filter to the FDA’s approved list since 1999. The U.S. lags behind the rapid development of UV filters in other countries because it is categorized as an over-the-counter drug. OTC drugs can be approved by the FDA either through a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) or by meeting the OTC monograph requirements, which do not need premarket approval. The OTC monograph process, including for sunscreens, faced challenges with outdated guidelines due to slow rulemaking. The CARES Act of 2020 addressed this by replacing lengthy rulemaking with a faster administrative order process and enabling the FDA to collect fees from manufacturers. This has allowed the FDA to more efficiently update OTC monographs. However, the timing of this process still lags.

 

In Korea, sunscreen is labeled as a cosmetic product. To approve a cosmetic product in Asia, clinical safety and efficacy documentation has to be submitted to the MFDS. This process is simpler and quicker than the system for sunscreen approval in the U.S. Here is a list of some of the UV filters approved in Korea but not the U.S.

  • Bemotrizinol (protects against UVA and UVB)
  • Uvasorb HEB (UVB)
  • Uvinul A Plus (UVA)
  • Parasol SLX (UVB)
  • Isoamyl p-Methoxy-cinnamate (UVB)

 

Innisfree Daily Uv Protection Cream Mild Spf35 Pa++ (contains Isoamyl p-Methoxy-cinnamate)

Anessa Whitening UV Sunscreen Gel A Spf50+ Pa++++ (contains Bemotrizinol)

SULWHASOO – UV Daily Essential Sunscreen Multi-Protection SPF 50+ (contains Uvinul A Plus)

author avatar
Dr. Jane Yoo Board-Certified Dermatologist and Mohs Surgeon
Jane Yoo, MD, MPP, is a Korean American board-certified dermatologist and fellowship-trained Mohs surgeon based in Midtown Manhattan. She is a Clinical Assistant Professor at the Icahn School of Medicine at Mount Sinai and the founder of Jane Yoo MD, PLLC and the Clinical Research Center of New York. Dr. Yoo holds an undergraduate degree from MIT and a Masters of Public Policy from Harvard's Kennedy School of Government. She completed her Mohs micrographic surgery fellowship at Yale. Her clinical and research focus spans aesthetic clinical trials including injectables and laser technology, skincare formulation and sunscreen science, K-Beauty and skin of color, ultrasound guided filler dissolution, artificial intelligence and beauty tech. Dr. Yoo's research is indexed under ORCID 0000-0002-7112-8963.